{"schema_version":"1","generated_at":"2026-10-28T04:01:54.461Z","data_as_of":null,"url":"https://www.findmykol.com/kol/marcus-messmer","json_url":"https://www.findmykol.com/kol/marcus-messmer/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"marcus-messmer","name":"Marcus Messmer","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Fox Chase Cancer Center","institution_url":"https://www.findmykol.com/institution/fox-chase-cancer-center","city":"Philadelphia","state":"PA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1285070490","orcid":"0000-0002-8030-1190","openalex":"A5051933958"},"summary":"Marcus Messmer is an Oncology physician affiliated with Fox Chase Cancer Center. OpenAlex indexes 44 publications with 2,381 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":44,"cited_by_count":2381,"h_index":11,"latest_activity_year":2025,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT06557330","title":"MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma","phase":"PHASE2","status":"NOT_YET_RECRUITING","role":"Overall official","sponsor":"Fox Chase Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT06557330","trial_url":"https://www.findmykol.com/trial/NCT06557330"}],"source":"trials"},"payments":{"company_count":23,"program_years":{"first":2021,"last":null},"rows_total":33,"shown":3,"withheld":30,"rows":[{"payer":"Incyte Corporation","program_year":2025,"amount_usd":15350,"payment_count":20,"source_url":"https://openpaymentsdata.cms.gov/search?query=1285070490"},{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":2981.23,"payment_count":5,"source_url":"https://openpaymentsdata.cms.gov/search?query=1285070490"},{"payer":"BeOne Medicines USA, Inc.","program_year":2025,"amount_usd":148.88,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1285070490"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1285070490","source":"payments"},"prescribing":{"data_year":2024,"areas_total":6,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":44.8,"classes_total":3,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":35.6,"drugs":[{"name":"Brukinsa","share_pct":74},{"name":"Calquence","share_pct":26}],"max_beneficiaries":null},{"class":"Methyltransferase Inhibitor","setting":"prescribed","share_pct":4.8,"drugs":[{"name":"Tazverik","share_pct":100}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":20.2,"classes_total":2,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":11.2,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":11},{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":9,"drugs":[{"name":"Ondansetron Hcl","share_pct":100}],"max_beneficiaries":16}]},{"area":"Nervous system","share_pct":16,"classes_total":3,"classes":[{"class":"Atypical Antipsychotic","setting":"prescribed","share_pct":8.1,"drugs":[{"name":"Olanzapine","share_pct":100}],"max_beneficiaries":11},{"class":"Other antidepressants","setting":"prescribed","share_pct":4.2,"drugs":[{"name":"Mirtazapine","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":38,"shown":5,"withheld":33,"matched_by":"OpenAlex author record","recent":[{"title":"NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025","year":2025,"journal":"Journal of the National Comprehensive Cancer Network","source_url":"https://doi.org/10.6004/jnccn.2025.0048","status":"verified"},{"title":"Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma","year":2025,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2025018527","status":"verified"},{"title":"“I Missed My Other Oncologist”: Established Relationships as Barriers and Facilitators to Accessing <scp>CAR</scp> ‐T and Autologous Transplantation","year":2025,"journal":"Cancer Medicine","source_url":"https://doi.org/10.1002/cam4.71425","status":"verified"},{"title":"Shelter in place: live CLL cells inside the bone marrow fibroblasts and its implication in residual disease persistence","year":2025,"journal":"Blood Neoplasia","source_url":"https://doi.org/10.1016/j.bneo.2025.100142","status":"verified"},{"title":"Harnessing BCL2 inhibition with BTK inhibition in follicular lymphoma: A translational trial with mechanistic insights from single cell analysis","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-3313","status":"verified"}],"source":"works"},"contact":{"address_1":"3401 N BROAD ST","city":"Philadelphia","state":"PA","zip":"191405103","phone":"215-707-4000","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1285070490","source":"identity"},"similar":[{"name":"Elizabeth Plimack","slug":"elizabeth-plimack","institution":"Fox Chase Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/elizabeth-plimack","json_url":"https://www.findmykol.com/kol/elizabeth-plimack/profile.json"},{"name":"Martin Edelman","slug":"martin-edelman","institution":"Fox Chase Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/martin-edelman","json_url":"https://www.findmykol.com/kol/martin-edelman/profile.json"},{"name":"Shazia Nakhoda","slug":"shazia-nakhoda","institution":"Fox Chase Cancer Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/shazia-nakhoda","json_url":"https://www.findmykol.com/kol/shazia-nakhoda/profile.json"},{"name":"Hossein Borghaei","slug":"hossein-borghaei","institution":"Fox Chase Cancer Center","specialty":"Magnetic Resonance Imaging (MRI)","url":"https://www.findmykol.com/kol/hossein-borghaei","json_url":"https://www.findmykol.com/kol/hossein-borghaei/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":30,"publications":33}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2021-07-07","provider_certified":"2021-07-07","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}